PLYMOUTH MEETING, Pa.,
Sept. 29, 2021 /PRNewswire/ -- INOVIO
(NASDAQ:INO), a biotechnology company focused on rapidly bringing
to market precisely designed DNA medicines to treat and protect
people from infectious diseases, cancer, and HPV-associated
diseases, will present three posters at IDWeek 2021, taking place
virtually from September
29th - October
3rd.
Dr. Laurent M. Humeau, INOVIO's
Chief Scientific Officer, said, "We are excited to participate in
our first IDWeek with the presentation of three posters that
confirm our approach of developing DNA vaccines to combat the
ongoing COVID-19 pandemic. Our vaccine candidates' study results
have demonstrated INOVIO's platform-wide safety and tolerability
profile, as well as the ability to generate CD8 and CD4 T cells and
neutralizing antibodies against SARS-CoV-2 and variants of concern.
We look forward to sharing our work with infectious disease experts
around the world and hope they find the results generated by DNA
COVID-19 vaccines to be very impactful."
The following abstracts and presentations are currently
available for meeting attendees viewing:
- Abstract #571: Safety and Immunogenicity of INO-4800, a
COVID-19 DNA Vaccine as a Primary Series and Booster
- Abstract #578: INO-4800 DNA Vaccine Induces Neutralizing
Antibodies and T cell Activity Against Global SARS-CoV-2
Variants
- Abstract #579: Design and immunogenicity of a Pan-SARS-CoV-2
synthetic DNA vaccine
About INOVIO's DNA Medicines Platform
INOVIO has 15 DNA medicine clinical programs currently in
development focused on HPV-associated diseases, cancer, and
infectious diseases, including coronaviruses associated with
COVID-19 and MERS. DNA medicines are composed of optimized DNA
plasmids, which are small circles of double-stranded DNA that are
synthesized or reorganized by a computer sequencing technology and
designed to produce a specific immune response in the body.
INOVIO's DNA medicines deliver optimized plasmids directly into
cells intramuscularly or intradermally using INOVIO's proprietary
hand-held smart device called CELLECTRA®. The
CELLECTRA® device uses a brief electrical pulse to
reversibly open small pores in the cell to allow the plasmids to
enter, which is designed to overcome a key limitation of other DNA
and other nucleic acid approaches, such as mRNA. Once inside the
cell, the DNA plasmids enable the cell to produce the targeted
antigen. The antigen is processed naturally in the cell and
triggers the desired T cell and antibody-mediated immune responses.
Administration with the CELLECTRA® device is designed to
ensure that the DNA medicine is efficiently delivered directly into
the body's cells, where it can go to work to drive an immune
response. INOVIO's DNA medicines do not interfere with or change in
any way an individual's own DNA. The advantages of INOVIO's DNA
medicine platform are how fast DNA medicines can be designed and
manufactured; the stability of the products, which do not require
freezing in storage and transport; and the robust immune response,
safety profile, and tolerability that have been observed in
clinical trials.
With more than 3,900 patients receiving INOVIO investigational
DNA medicines in more than 12,000 applications across a range of
clinical trials, INOVIO has a strong track record of rapidly
generating DNA medicine candidates with potential to meet urgent
global health needs.
About INOVIO
INOVIO is a biotechnology company focused on rapidly bringing to
market precisely designed DNA medicines to treat and protect people
from infectious diseases, cancer, and diseases associated with HPV.
INOVIO is the first company to have clinically demonstrated that a
DNA medicine can be delivered directly into cells in the body via a
proprietary smart device to produce a robust and tolerable immune
response. Specifically, INOVIO's lead candidate VGX-3100 met
primary and secondary endpoints for all evaluable subjects in
REVEAL 1, the first of two, Phase 3 trials for precancerous
cervical dysplasia, demonstrating ability to destroy and clear both
high-grade cervical lesions and the underlying high-risk HPV-16/18.
INOVIO is also evaluating INO-4800, a DNA vaccine candidate against
COVID-19, in a global Phase 3 clinical trial, as well as Phase 2
trials in China and South Korea.
Partners and collaborators include Advaccine, ApolloBio
Corporation, AstraZeneca, The Bill & Melinda Gates Foundation,
Coalition for Epidemic Preparedness Innovations, Defense Advanced
Research Projects Agency/Joint Program Executive Office for
Chemical, Biological, Radiological and Nuclear Defense/Department
of Defense, HIV Vaccines Trial Network, International Vaccine
Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium,
National Cancer Institute, National Institutes of Health, National
Institute of Allergy and Infectious Diseases, Ology Bioservices,
the Parker Institute for Cancer Immunotherapy, Plumbline Life
Sciences, Regeneron, Richter-Helm BioLogics, Thermo Fisher
Scientific, University of Pennsylvania,
Walter Reed Army Institute of Research, and The Wistar Institute.
For more information, visit www.inovio.com.
CONTACTS:
Media: Jeff Richardson,
267-440-4211, jrichardson@inovio.com
Investors: Ben Matone, 484-362-0076,
ben.matone@inovio.com
This press release contains certain forward-looking
statements relating to our business, including our plans to develop
DNA medicines, our plans and expectations regarding manufacturing,
our plans regarding development of an in-vitro diagnostic, our
expectations regarding our research and development programs,
including the planned initiation and conduct of preclinical studies
and clinical trials and the availability and timing of data from
those studies and trials, and our ability to successfully
manufacture and produce large quantities of our product candidates
if they receive regulatory approval. Actual events or results may
differ from the expectations set forth herein as a result of a
number of factors, including uncertainties inherent in pre-clinical
studies, the structuring, initiation and outcomes of clinical
trials, product development programs and commercialization
activities and outcomes, our ability to secure sufficient
manufacturing capacity to mass produce our product candidates, the
availability of funding to support continuing research and studies
in an effort to prove safety and efficacy of electroporation
technology as a delivery mechanism or develop viable DNA medicines,
our ability to support our pipeline of DNA medicine products, the
ability of our collaborators to attain development and commercial
milestones for products we license and product sales that will
enable us to receive future payments and royalties, the adequacy of
our capital resources, the availability or potential availability
of alternative therapies or treatments for the conditions targeted
by us or our collaborators, including alternatives that may be more
efficacious or cost effective than any therapy or treatment that we
and our collaborators hope to develop, issues involving product
liability, issues involving patents and whether they or licenses to
them will provide us with meaningful protection from others using
the covered technologies, whether such proprietary rights are
enforceable or defensible or infringe or allegedly infringe on
rights of others or can withstand claims of invalidity and whether
we can finance or devote other significant resources that may be
necessary to prosecute, protect or defend them, the level of
corporate expenditures, assessments of our technology by potential
corporate or other partners or collaborators, capital market
conditions, the impact of government healthcare proposals and other
factors set forth in our Annual Report on Form 10-K for the year
ended December 31, 2020, our
Quarterly Report on Form 10-Q for the quarter ended June 30, 2021 and other filings we make from time
to time with the Securities and Exchange Commission. There can be
no assurance that any product candidate in our pipeline will be
successfully developed, manufactured or commercialized, that final
results of clinical trials will be supportive of regulatory
approvals required to market products, or that any of the
forward-looking information provided herein will be proven
accurate. Forward-looking statements speak only as of the date of
this release, and we undertake no obligation to update or revise
these statements, except as may be required by law.
View original
content:https://www.prnewswire.com/news-releases/inovio-to-present-three-posters-at-idweek-2021-301387566.html
SOURCE INOVIO Pharmaceuticals, Inc.